Elutia Inc (ELUT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 43 | 47 | 24 | 25 | 24 | 12 | 12 | 8 |
| Operating profit | $m | -18 | -24 | ||||||
| Net profit | $m | -22 | -25 | -33 | -38 | -54 | 53 | 52 | -29 |
| EPS reported | $ | 0.87 | 0.94 | ||||||
| Operating cashflow per share | $ | -1.08 | -0.99 | ||||||
| Capex per share | $ | 0.05 | 0.03 | ||||||
| FCF per share | $ | -1.13 | -1.03 | ||||||
| Free cash flow | $m | -47 | -45 | ||||||
| Net debt | $m | -29 | -13 | ||||||
| Book value equity | $m | 28 | 16 | ||||||
| Book value per share | $ | 0.60 | 0.36 | ||||||
| Number of shares | m | 45.94 | 43.62 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 0.80 | 0.86 | ||||||
| P/B LTM | x | 1.04 | 1.82 | ||||||
| P/S LTM | x | 2.33 | 2.36 | ||||||
| P/FCF LTM | x | -0.61 | -0.63 | ||||||
| EV/EBITDA LTM | x | -0.26 | -0.15 | ||||||
| EV/Sales LTM | x | 0.29 | 2.15 | ||||||
| Earnings Yield LTM | % | +125.00% | +116.28% | ||||||
| FCF Yield | % | -162.73% | -158.51% | ||||||
| Quality | |||||||||
| ROE | % | +192.90% | +940.81% | ||||||
| ROIC | % | -43.87% | -1.01% | ||||||
| Operating margin | % | -1.50% | -1.94% | ||||||
| Gross margin | % | +53.66% | +57.82% | ||||||
| FCF/Sales | % | -379.78% | -374.76% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -49.57% | -50.22% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.18 | -4.21 | ||||||
| Net Debt/EBITDA | x | 1.87 | 0.63 | ||||||
| EBIT/Net interest | x | 47.58 | 6.77 | ||||||
| Net debt/market cap | % | +26.43% | +10.53% | ||||||
| Net debt/Equity | x | -1.04 | -0.86 | ||||||
| Gross debt/equity | x | 0.40 | 0.69 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free